Coming soon: Experts' findings on use of ivermectin to treat, prevent COVID-19 | Inquirer News

Coming soon: Experts’ findings on use of ivermectin to treat, prevent COVID-19

/ 09:57 AM April 12, 2021

FDA to Garin: Hospital got ivermectin permit upon application

A number of physicians swear by the effectiveness of ivermectin, an antiparasitic drug commercially available only for veterinary use, as a treatment or preventive medicine against COVID-19. But the Food and Drug Administration maintains there are procedures to be followed, including clinical trials, before the drug could be allowed for distribution. —AFP

MANILA, Philippines — The Department of Health (DOH) has already obtained results from the experts’ evaluation of ivermectin for COVID-19 treatment, but the results have yet to be finalized, Health Undersecretary Maria Rosario Vergeire said Monday.

“Our experts have been evaluating this ivermectin for these past weeks and we have already results from this evaluation. We just need to finalize the report and then we will inform the public,” she said in an interview on ABS-CBN News Channel.

In an online press briefing, Vergeire said that the Philippine COVID-19 Living CPG Reviewers’ evaluation of ivermectin is “almost complete.”

Article continues after this advertisement

She said that the results may be out in the coming days or weeks.

FEATURED STORIES

Vergeire then advised the public to wait for ivermectin to be registered for COVID-19 prevention and treatment in the country before using it against the respiratory disease.

“This is just what we are saying, let’s just wait for the advise of our experts. It’s not going to be long. Let’s just wait for this drug to be registered here in the country so that government can also be able to monitor and be able to be accountable if ever you will take that drug,” she added.

Article continues after this advertisement

Health Undersecretary Rosario Vergeire

Health Undersecretary Rosario Vergeire (INQUIRER FILE PHOTO / EDWIN BACASMAS)

Vergeire stressed that the government cannot guarantee the safety of ivermectin as it is still unregistered for human use in the country.

Article continues after this advertisement

She added that those using the product may also have a false sense of protection against COVID-19.

Article continues after this advertisement

“We base everything on science. We cannot just settle for everything that just because other countries are using it, because all of our citizens are already using it then we just go with the flow and give them the go signal,” Vergeire said.

“The DOH and FDA (Food and Drug Administration) has that mandate of protecting the population, public health, and we have that mandate of ensuring that all of these drugs that you take will be safe and of quality,” she added.

Article continues after this advertisement

The FDA earlier granted a compassionate special permit for a hospital’s use of ivermectin for COVID-19 patients. 

An application for a certificate of product registration for human use of ivermectin filed by Lloyd Laboratories Inc. is also pending before the FDA. 

gsg
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: COVID-19, DoH, Ivermectin

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.